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Muzaffar H. Qazilbash,1 Ali Imran Amjad,2 Suhail Qureshi,1 Sofia R Qureshi,1
Rima M. Saliba,1 Ziad U. Khan,3 Chitra Hosing,1 Sergio A Giralt,1 Marcos J. De Lima,1
Uday R Popat,1 Syed W. Yusuf,4 Richard E. Champlin1A high risk of regimen-related toxicity with allogeneic hematopoietic stem cell transplantation (allo-HSCT)
limits this potentially curative treatment for patients with a left ventricular ejection fraction (LVEF) of$50%.
We evaluated the frequency of cardiac complications and 100-day nonrelapse mortality (NRM) in 56 patients
with a LVEF of#45%, who received allo HCTat our institution. The results were retrospectively compared
with a matched control group with LVEF of $50%, which received an allogeneic stem cell transplantation
(allo-SCT). After a median follow-up of 29 months in the study group, grade $2 cardiac complications
were seen in 7 of 56 (12.5%) patients and cumulative incidence of 100-day NRM was 12.5% with no deaths
from cardiac causes. In contrast, after a median follow-up of 49 months in the control group, grade .2 car-
diac complications were seen in 19 of 161 patients (11.8%; P 5 1.00) and cumulative incidence of 100-day
NRM was 14.9% (P5 .82). The presence of at least 1 of the 7 pretransplant cardiac risk factors (past history
of smoking, hypertension, hyperlipidemia, coronary artery disease, arrhythmia, prior myocardial infarction,
and congestive heart failure) was associated with a higher cardiac complication rate in the study group (P5
.03). In conclusion, selected patients with a LVEF of #45% can safely receive allo-HCTwithout a significant
increase in cardiac toxicity or NRM.
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High-dose chemotherapy followed by an alloge-
neic hematopoietic stem cell transplant (allo-HSCT)
is potentially curative for various benign and malig-
nant diseases [1]. Because of a high risk of nonre-
lapse mortality (NRM) and other life-threatening1Stem Cell Transplantation and Cellular Therapy,
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tients with adequate vital organ functions are consid-
ered for this procedure [2-6]. Accordingly, patients
with a left ventricular ejection fraction (LVEF) of
\50% are considered ineligible for allo-HSCT to
exclude those at a higher risk of NRM from cardiac
causes [2-6]. However, the validity of this pretrans-
plant cardiac assessment as a predictor for cardiac
complications and/or mortality is not established,
and may deny a potentially curative treatment to pa-
tients with no alternate therapeutic options.
Bidimensional echocardiogram (2D-echo) or multi-
gated acquisition cardiac (MUGA) scan are useful tools
to evaluate LVEF, a surrogate marker of cardiac func-
tion [7]. Two-dimensional (2D) echocardiography al-
lows real-time imaging of the heart and its various
structures using ultrasonic waves. Estimation of the
LVEF by 2D echocardiography can be done either qual-
itatively by visual inspection of global and regional func-
tion or quantitatively, using geometric assumptions
regarding the shape of the LV cavity. 2D echocardiogra-
phy has several shortcomings, including interobserver
and intraobserver variability, limited diagnostic value1265
1266 Biol Blood Marrow Transplant 15:1265-1270, 2009M. H. Qazilbash et al.in patients with poor acoustic windows, such as obese in-
dividuals, patients with hyperinflated lungs because of
obstructive lung diseases, and patients with musculo-
skeletal deformities like kyphosis or pectus excavatum
[7].
We performed this retrospective analysis to study
the safety of allo-HSCT in patients with low LVEF
(#45%), and to assess its impact on post-allo HSCT
cardiac complications and NRM. The outcomes
were retrospectively compared with a matched control
group undergoing an allogenic stem cell transplanta-
tion (allo-SCT) with a normal LVEF ($50%).Table 1. Patient and Disease Characteristics
Study Group Control
Characteristic
Number
n 5 56 (%)
Number
N 5 161 (%) P-Value
Sex
Male 40 (71) 95 (59) .11
Female 16 (29) 66 (41)
Median age (years) 43.5 (range: 18-70) 51 (range: 20-71) .01
Diagnosis
AML/MDS 23 (41) 69 (43) .87
ALL 9 (16) 18 (11)
Lymphoma 12 (21) 38 (24)
Hodgkin disease 4 (7) 12 (7)
CML 3 (5) 11 (7)
CLL 1 (2) 5 (3)
Multiple myeloma 2 (4) 8 (5)
Systemic sclerosis 2 (4) 0 (0)
Disease status*
Low risk 9 (16) 23 (14) .75
Intermediate risk 14 (25) 49 (30)
High risk 33 (59) 89 (55)
Donor type
Related 28 (50) 91 (57) .43
HLA-matched 23 (41) 85
HLA-mismatched 5 (9) 6
Unrelated 28 (50) 70 (43)
HLA-matched 23 (41) 62
HLA-mismatched 5 (9) 8
Preparative regimens
Myeloablative, 21 (37) 59 1.00
RIC 35 (62) 102
Pre-allo-HSCT LVEF (%)
>50 0 161 .0001
#45 25 (45)
#40 21 (37)
#35 10 (18)
Risk factors for cardiac complications†
Yes 35 (62.5) 97 (60) .87
No 21 (37.5) 64 (40)
Cyclophosphamide in preparative regimen
Yes 17 (30) 39 (24) .37
No 39 (70) 122 (76)
RIC indicates reduced-intensity conditioning; AML, acute myelogenous
leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloge-
nous leukemia; CLL, chronic lymphocytic leukemia; allo-HSCT, alloge-
neic hematopoietic stem cell transplantation; LVEF, left ventricular
ejection fraction; MDS, myelodysplastic syndromes.
*Low-risk: CML chronic phase #1, CR1 for all other diseases; Interme-
diate-risk: CML in equal to or greater than second chronic phase, CR2
or beyond for all other diseases; High risk: CML in accelerated or blast
phase; relapsed or refractory disease for all other diseases.
†Risk factors include smoking, hypertension, hyperlipidemia, coronary
artery disease, arrhythmia, myocardial infarction, or congestive heart
failure.MATERIALS AND METHODS
Patients
We reviewed our database for patients with
a LVEF of 45% or lower, who received allo-HSCT
between January of 2000 and February of 2006 at the
University of Texas, M.D. Anderson Cancer Center.
A total of 56 patients were eligible for this analysis.
LVEF was measured within 30 days pretransplant,
either by a 2D-echo or a MUGA scan. Patients
provided informed consent to receive allo-HSCT in
accordance with the Declaration of Helsinki. This
retrospective study was approved by the institutional
review board. We grouped the patients into high-,
intermediate-, and low-risk categories, based on the
disease status at allo-HSCT (Table 1).
Risk Factors
We studied 7 risk factors (history of smoking,
hypertension, hyperlipidemia, coronary artery disease,
cardiac arrhythmias, prior acute myocardial infarction,
and congestive heart failure [CHF]) that may increase
the incidence of posttransplant cardiac complications
and mortality. Thirty-five patients (62%) in the study
group had 1 or more of these risk factors prior to
allo-HSCT.
Control Group
We compared their outcome of the study group
with a control group of 161 patients, who received
allo-SCT at the same time, and were matched for
age, diagnosis, risk factors and disease status. Ninety-
seven patients in the control group (60%; P 5 .87)
had 1 or more cardiac risk factors.
Endpoints
Primary endpoints were grade 2 or higher cardiac
complications and 100-day NRM. Cardiac complica-
tions were defined according to National Cancer
Institute (NCI) Common Terminology Criteria for
Adverse Events, Version 3.0 (CTCAE v3.0) [8]. These
included grade $2 cardiac complications under thecategories of arrhythmia, CHF, and cardiac ischemia
(Table 2). NRM was defined as death occurring in
the absence of progression or relapse of underlying
disease. The cumulative incidence method was used
to estimate NRM considering death attributed to
underlying disease as a competing risk; and the risk
of cardiac toxicity considering death in the absence
of cardiac toxicity as a competing risk. Secondary
endpoint was 3-year actuarial overall survival (OS)
estimated by the method of Kaplan and Meier. Impact
of risk factors on the outcome was evaluated with
univariate analysis using the Cox’s proportional
Table 2. Grading of Cardiac Complications after allo-HSCT*
Grade
Cardiac
Complication 1 2 3 4 5
Arrhythmia Asymptomatic,
intervention
not indicated
Nonurgent medical
intervention indicated
Incompletely controlled,
medically or with
device (eg, pacemaker)
Life-threatening
(eg, associated with CHF,
hypotension, syncope, shock
Death
Congestive
Heart Failure
Asymptomatic
diagnostic
finding; intervention
not indicated
Asymptomatic,
intervention
indicated
Symptomatic CHF
responsive to intervention
Refractory CHF, poorly
controlled; intervention
such as ventricular assist
device or heart transplant
indicated
Death
Cardiac
Ischemia
Asymptomatic arterial
narrowing without
ischemia
Asymptomatic and
testing suggesting
ischemia;
stable angina
Symptomatic; testing
consistent with ischemia;
unstable angina;
intervention needed
Acute myocardial
infarction
Death
CHF indicates congestive heart failure; allo-HSCT, allogeneic hematopoietic stem cell transplantation.
Adapted from Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0), DCTD, NCI, NIH,
DHHS.
Biol Blood Marrow Transplant 15:1265-1270, 2009 1267Allo-HCT in low LVEFhazards model. All P values are 2 sided. Statistical
analyses were carried out using STATA 9.0 software.RESULTS
Patient characteristics for the study and the control
groups are summarized in Table 1. Median age was
43.5 years (range: 18-70 years) for the study group
and 51 years (20-71 years) for the control group. As
shown in Table 1, other than LVEF (P5 .0001) there
was no significant difference between the study and the
control groups in terms of diagnosis, disease status, do-
nor type, preparative regimen, or cardiac risk factors.
Baseline LVEF was measured by either 2D-echo or
a MUGA scan and ranged from 20% to 45% in the
study group and 50% to 65% in the control group
(Table 1).
Cardiac Complications
After a median follow-up of 29 months (range:
11-82) in the study group, Grade$2 cardiac complica-
tions were seen in 7 of 56 (12.5%) patients. These
adverse events included CHF in 4 (7.%) and atrial
fibrillation (AF) in 4 (7%) patients. One patient had
both CHF and AF. There were no documented
episodes of acute coronary ischemia or deaths directly
related to cardiac events. Cardiac complications were
seen in 7 of 35 patients (20%), with at least 1 of the 7 car-
diac risk factors pre-allo-HSCT. In contrast, none of the
21 patients without a cardiac risk factors developed a car-
diac complication (P5 .03). On univariate analysis, vari-
ables such as age, diagnosis, sex, type of donor, intensity
of preparative regimen (myeloablative [MA] versus re-
duced-intensity conditioning [RIC]), or exposure of cy-
clophosphamide (Cy) did not emerge as significant
predictors of posttransplant cardiac complications
(Table 3).
Median follow-up in the control group was
49 months (range: 1-98 months). Grade .2 cardiaccomplications were seen in 19 of 161 patients
(11.8%; P 5 1.00). Cardiac complications were seen
in 15 of 97 patients with at least 1 of the 7 cardiac
risk factors pre-allo-HSCT and in 4 of 64 patients
without any cardiac risk factors (P 5 .08). These ad-
verse events included CHF in 8 patients, arrythmias
(mainly AF) in 15, and acute ischemic episodes in 5
patients. Seven patients had a combination of 2 or 3
cardiac events.
100-Day NRM
Overall, 7 patients died of nonrelapse causes within
the first 100 days in the study group, with a cumulative
NRM of 12.5%. None of the deaths were directly
related to cardiac complications. The causes of death
were as follows: multiorgan failure/sepsis (n 5 4),
acute graft-versus-host disease (aGVHD; n 5 2), and
diffuse alveolar hemorrhage (DAH; n 5 1). NRM at
100 days was 10.0%, 14.3%, and 12.0% in patients
with pre-allo-HSCT LVEF of #35%, #40%, and
#45%, respectively. On univariate analysis, variables
such as age, sex, type of donor, intensity of preparative
regimen (MA versus RIC), or the underlying disease
did not emerge as significant predictors of NRM
(Table 3).
In the control group, 24 patients died of nonrelapse
causes within the first 100 days (14.9%; P 5 .82). The
causes of death were as follows: multiorgan failure/sep-
sis (7), aGVHD (9), idiopathic pneumonia syndrome
(4), graft failure (1), and other (3). As in the study group,
no deaths were directly attributable to cardiac causes.
Survival
Kaplan-Meier estimate of 3-year OS was 32% for
the study group and 45% for the control group
(P 5 .08) (Figure 1). Donor type was the only signifi-
cant predictor of OS, with recipients of a matched re-
lated graft having a significantly lower mortality rate
(hazard ratio [HR] 5 0.4, P 5 .02). At the time of
Table 3. Impact of Prognostic factors on Outcome
NRM at Day 100 Risk of Cardiac Complications
N HR 95% CI P-Value HR 95% CI P- Value
Age
#43 28 Ref. Ref.
>43 28 2.6 0.5-13.4 0.25 2.9 0.6-15.2 .2
HCT-CI
1-2 39 Ref
>2 17 0.9 0.2-4.5 0.9 0.3 0.04-2.8 0.3
Donor type
Matched related 23 0.2 0.02-1.4 0.1 0.5
Matched unrelated 23 Ref. Ref. 0.8
Mismatched 10 0.4 0.05-3.8 0.5 can’t estimate
Pre-TP LVEF
#35 10 Ref. Ref.
36-40 21 1.6 0.2-15.1 0.7 1.6 0.2-16 0.7
>40 25 1.3 0.1-13 0.8 1.3 0.1-12.5 0.8
Smoking status
Smoker 20 0.7 0.1-3.4 0.6 3.9 0.7-20.2 0.1
Nonsmoker 36 Ref.
Prep regimen
Ablative 21 0.7 0.1-3.4 0.6 0.2 0.03-2.0 0.2
Reduced intensity 35 Ref.
Cyclophosphamide in prep regimen
Yes 17 0.9 0.2-4.7 0.9 1.6 0.3-6.9 0.6
No 39 Ref.
Diagnosis
Acute leukemia 32 Ref. Ref.
Lymphoma 16 1.5 0.2-8.8 0.7 1.4 0.2-8.4 0.7
Others 8 3 0.5-17.9 0.2 3.5 0.5-18.3
NRM indicates nonrelapse mortality; HR, hazard ratio; CI, confidence interval; HCT-CI, hematopoietic stem cell transplantation comorbidity index; TP,
transplant; Prep regimen, preparative regimen.
1268 Biol Blood Marrow Transplant 15:1265-1270, 2009M. H. Qazilbash et al.last follow-up, 39 patients in the study group had died,
18 because of disease progression, and 21 because of
nonrelapse causes, with aGVHD or chronic GVHD
(cGVHD) being the most common cause of NRM (6
patients: 10%).Figure 1. Kaplan-Meier estimate of OS in study and control groups.DISCUSSION
Our results suggest that patients with an LVEF of
\45% can safely undergo an allo-HSCT. We ob-
served a cardiac complication rate of 12.5% in 56 pa-
tients who received allo-HSCT and had a low LVEF
(#45%). The 100-day NRM and 3-year OS were
12.5% of 32%, respectively, with no early mortality
related to cardiac causes. These rates were comparable
to a control group of 161 patients that matched the
study group in almost all parameters, except for an
older age and a normal LVEF (50%-65%). Both
NRM and OS in the study group are acceptable given
the high-risk patient population, where 33 (59%)
patients had relapsed or refractory disease and
14 (25%) were in second remission or beyond [3,9,10].
Cardiac toxicity in the immediate post-alllo-HCT
period is reported in 0.9% to 43% of patients [2,11-
17]. These complications include cardiomyopathy,
arrhythmias, ischemic events, CHF, pericarditis,
tamponade, and death because of cardiac compromise.
Many factors, including Cy, anthracyclines, total bodyirradiation (TBI), prior mediastinal radiotherapy, and
transfusion associated iron overload increase the risk
of post-alllo-HCT cardiac complications [4,5,18-23].
Murdych et al. [14] reported a serious cardiac compli-
cation rate of only 0.9% in a large cohort of patients (n
5 2821). A higher incidence is reported by others with
varying definitions of cardiac toxicity. Incidentally, the
majority of patients in these studies had a pretransplant
LVEF of $50%, considered an acceptable range for
allo-HSCT [21]. Other groups have also reported car-
diac complication rate in patients with low LVEF
Biol Blood Marrow Transplant 15:1265-1270, 2009 1269Allo-HCT in low LVEF(cutoffs varying from #55% to #40%). However, the
number of patients in those reports was smaller than 56
patients reported by us: Yoshimi et al. [6] 6.7% (1 of
15); Sakata-Yanagimoto et al. [4] 11.1% (2 of 18);
Bearman et al. [2] 20.0% (2 of 10); and Fujimaki
et al. [3] 42.9% (3 of 7).
We analyzed the impact of factors other than
LVEF that may predispose a patient to post-al-
lo-HSCT cardiac complications, including smoking,
hypertension, hyperlipidemia, coronary artery disease,
arrhythmia, prior infarction, and CHF We found that
patients with at least 1 of these 7 risk factors pre-allo-
HSCT were significantly more likely to develop car-
diac complications when compared to patients without
them. These risk factors may be incorporated in
a prognostic model to predict the risk of cardiac
complications in patients with low LVEF. If validated,
this approach may help in identifying a high-risk
population that may benefit from therapeutic interven-
tion to reduce the risk of cardiac toxicity.
We evaluated the impact of various prognostic factors
on cardiac toxicity and NRM in a univariate analysis.
None of these, including high-dose Cy, age, diagnosis,
comorbidity index (HCT-CI), as reported by Sorror
et al. [24,25], emerged as significant predictors of out-
come. That may be because of the inherent limitations
of a retrospective analysis, including the variability in
therapeutic agents, doses, and their potential for cardio-
toxicity, small sample size, and heterogeneity of diagnosis
and treatments.
In summary, selected patients with LVEF #45%
can safely undergo allo-HSCT with acceptable risk
of cardiac complications, NRM, and OS.AUTHORSHIP
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